| Arrestin Beta 1 | |
|---|---|
| Gene Symbol | ARRB1 |
| Full Name | Arrestin beta 1 |
| Chromosome | 11q13.1 |
| NCBI Gene ID | [409](https://www.ncbi.nlm.nih.gov/gene/409) |
| OMIM | 107940 |
| Ensembl ID | ENSG00000141428 |
| UniProt ID | [P49407](https://www.uniprot.org/uniprot/P49407) |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease |
ARRB1 (Arrestin Beta 1), also known as β-arrestin 1, is a member of the arrestin family of proteins that plays a crucial role in regulating G protein-coupled receptor (GPCR) signaling 1. Arrestins bind to phosphorylated GPCRs, blocking further G protein coupling and promoting receptor internalization through clathrin-coated pits 2. Beyond receptor desensitization, ARRB1 serves as signaling scaffolds, activating pathways including MAPK, Akt, and PI3K 3. In the nervous system, ARRB1 regulates neurotransmission, synaptic plasticity, and neuronal survival. Dysregulated arrestin signaling is implicated in neurodegenerative diseases and psychiatric disorders.
The ARRB1 gene is located on chromosome 11q13.1 and encodes a 418-amino acid protein with a molecular weight of approximately 46 kDa. The protein adopts a typical arrestin fold:
N-terminal domain (residues 1-210):
C-terminal domain (residues 211-418):
ARRB1 shares approximately 70% sequence identity with ARRB2 (arrestin beta 2), with the highest conservation in the central polar core and the C-terminal domain 4.
ARRB1 functions as a master regulator of GPCR signaling 5:
Receptor phosphorylation recognition: When GPCRs are activated, they are phosphorylated by G protein-coupled receptor kinases (GRKs). ARRB1 recognizes these phosphorylated receptors through multiple phosphate sensors in its N-terminal domain.
G protein uncoupling: Upon binding to phosphorylated receptors, ARRB1 undergoes a conformational change that blocks further G protein coupling, effectively terminating G protein-mediated signaling.
Internalization: ARRB1 recruits clathrin and adaptor protein complex AP2 to the receptor, promoting internalization through clathrin-coated pits. The C-terminal domain of ARRB1 contains clathrin box motifs that directly interact with clathrin.
Beyond desensitization, ARRB1 serves as a signaling scaffold 6:
MAPK pathway activation: ARRB1 recruits components of the MAPK cascade (Raf, MEK, ERK) to activated receptors, enabling G protein-independent signaling. This is particularly important for β-adrenergic and angiotensin receptors.
Akt signaling: ARRB1 can activate Akt/PKB pathway through recruitment of PI3K, promoting cell survival and metabolic regulation.
β-catenin signaling: In some contexts, ARRB1 regulates β-catenin degradation through interaction with β-TrCP, affecting gene transcription and cell proliferation.
In neurons, ARRB1 performs several critical functions:
Receptor regulation: ARRB1 regulates neurotransmitter receptors including dopamine, serotonin, glutamate, and GABA receptors. This controls the strength and duration of synaptic signaling.
Synaptic plasticity: Through regulation of AMPA receptor trafficking and signaling, ARRB1 influences long-term potentiation (LTP) and long-term depression (LTD), cellular correlates of learning and memory 7.
Dendritic spine morphology: ARRB1 affects spine shape and density through regulation of cytoskeletal dynamics and receptor signaling at excitatory synapses.
Neuronal survival: ARRB1-mediated Akt signaling provides pro-survival signals that protect neurons from various insults.
ARRB1 is widely expressed throughout the brain:
Peripheral expression includes heart, lung, spleen, and immune cells.
ARRB1 is implicated in Alzheimer's disease pathogenesis through multiple mechanisms 8:
Amyloid receptor signaling: ARRB1 regulates amyloid precursor protein (APP) processing and amyloid-beta (Aβ) production through modulation of APP-processing enzymes. Aβ affects ARRB1 expression and function in neurons.
Tau pathology: ARRB1 signaling influences tau phosphorylation through regulation of tau kinases and phosphatases. The balance of ARRB1-mediated signaling affects tau pathology progression.
Synaptic dysfunction: ARRB1 dysregulation contributes to impaired synaptic plasticity in AD. Changes in ARRB1 affect AMPA receptor trafficking and NMDA receptor signaling, disrupting LTP.
Neuroinflammation: In microglia, ARRB1 regulates inflammatory responses to Aβ and other stimuli. Altered ARRB1 function may contribute to chronic neuroinflammation.
Therapeutic implications: Enhancing ARRB1-mediated neuroprotective signaling while reducing desensitization of protective receptors may provide therapeutic benefit in AD.
ARRB1 plays several roles in Parkinson's disease 9:
Dopamine receptor regulation: ARRB1 controls dopamine receptor (D1R, D2R) signaling and trafficking. Dysregulated ARRB1 affects dopaminergic transmission and motor control.
Alpha-synuclein toxicity: ARRB1 interacts with alpha-synuclein pathology. The receptor's signaling functions may be altered by α-synuclein aggregates, contributing to synaptic dysfunction.
Mitochondrial function: ARRB1-mediated signaling influences mitochondrial dynamics and quality control. Alterations may contribute to the mitochondrial dysfunction characteristic of PD.
Neuroprotection: ARRB1 activates pro-survival pathways that may protect dopaminergic neurons from various insults. Enhancing this signaling is being explored therapeutically.
Huntington's disease: ARRB1 signaling is altered in HD models and patients, affecting dopamine and glutamate receptor function. The receptor may be involved in the motor and cognitive symptoms of HD 10.
Amyotrophic lateral sclerosis (ALS): ARRB1 function is perturbed in motor neurons from ALS patients and models. The receptor's role in excitotoxicity and neuroinflammation may be relevant.
Stroke and traumatic brain injury: ARRB1-mediated neuroprotective signaling may be therapeutic target. Modulating receptor internalization and signaling affects outcomes after brain injury.
Multiple sclerosis: In immune cells, ARRB1 regulates cytokine production and migration, potentially affecting autoimmune responses.
ARRB1 is a therapeutic target for neurodegenerative diseases:
Bias ligands: GPCR ligands that selectively activate β-arrestin signaling (biased agonists) may provide neuroprotective effects without causing receptor desensitization. Several biased ligands are in development 11.
ARRB1 modulators: Small molecules that enhance or inhibit ARRB1 function could have therapeutic applications. However, achieving receptor specificity is challenging.
Gene therapy: Viral vector delivery of ARRB1 or modified ARRB1 variants to specific brain regions may restore receptor signaling deficits.
ARRB1 interacts with numerous proteins: